Intelligent Bio Solutions Aims to Slash Drug Testing Time by 70% in Validation Study

Event summary

  • Intelligent Bio Solutions (INBS) launched a validation study to reduce drug screening time from 10 minutes to under 3 minutes.
  • The study targets the $1.62 billion U.S. roadside drug testing market projected by 2030.
  • Current system collects samples in under a minute and provides results in 10 minutes.
  • Company aims for FDA 510(k) clearance for its Intelligent Fingerprinting Drug Screening System.

The big picture

The validation study positions INBS to capitalize on the surging demand for rapid, non-invasive drug testing solutions in law enforcement and other verticals. The global drug screening market is projected to grow at a 14% CAGR through 2030, with time-to-result becoming a critical differentiator. Success in this study could significantly enhance INBS's competitive advantage as states expand drug testing programs following marijuana legalization.

What we're watching

Regulatory Pathway
Whether INBS can secure FDA 510(k) clearance for broader U.S. market access.
Market Expansion
The pace at which faster testing times can capture high-value verticals beyond workplace testing.
Competitive Positioning
How sub-3-minute results will differentiate INBS in the growing global drug screening market.